Current Report Filing (8-k)
January 13 2020 - 8:32AM
Edgar (US Regulatory)
0001446847
false
0001446847
2020-01-12
2020-01-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January
13, 2020
IRONWOOD PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-34620
|
|
04-3404176
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
|
|
Identification
Number)
|
100 Summer Street, Suite 2300
|
|
|
Boston, Massachusetts
|
|
02110
|
(Address
of principal
|
|
(Zip
code)
|
executive
offices)
|
|
|
(617) 621-7722
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Class A
common stock, $0.001 par value
|
IRWD
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
Beginning on January 13, 2020, Ironwood
Pharmaceuticals, Inc. (the “Company”) intends to use the presentation (the “Corporate Presentation”)
furnished herewith, or portions thereof, which provides updates on the Company’s recent business activities, in one or more
meetings with or presentations to investors. The Corporate Presentation contains information regarding the Company’s
results of operations for 2019. A copy of the Corporate Presentation is furnished as Exhibit 99.1 and is incorporated
herein by reference.
The Corporate Presentation is being furnished
pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of
that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Corporate Presentation
|
104
|
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Ironwood Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Dated: January 13, 2020
|
By:
|
/s/ Gina
Consylman
|
|
|
Name: Gina Consylman
|
|
|
Title: Senior Vice President, Chief Financial
Officer
|
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Sep 2023 to Sep 2024